262 related articles for article (PubMed ID: 38051964)
1. Advancements in Novel Live Biotherapeutic Products for Clostridioides difficile Infection Prevention.
Lavoie T; Appaneal HJ; LaPlante KL
Clin Infect Dis; 2023 Dec; 77(Suppl 6):S447-S454. PubMed ID: 38051964
[TBL] [Abstract][Full Text] [Related]
2. Microbiota restoration therapies for recurrent
DuPont HL; DuPont AW; Tillotson GS
Therap Adv Gastroenterol; 2024; 17():17562848241253089. PubMed ID: 38800353
[TBL] [Abstract][Full Text] [Related]
3. The role of the gut microbiome in colonization resistance and recurrent
Seekatz AM; Safdar N; Khanna S
Therap Adv Gastroenterol; 2022; 15():17562848221134396. PubMed ID: 36425405
[TBL] [Abstract][Full Text] [Related]
4. Gut microbiota changes associated with
Gonzales-Luna AJ; Carlson TJ; Garey KW
Gut Microbes; 2023; 15(1):2223345. PubMed ID: 37318134
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection.
Khanna S; Assi M; Lee C; Yoho D; Louie T; Knapple W; Aguilar H; Garcia-Diaz J; Wang GP; Berry SM; Marion J; Su X; Braun T; Bancke L; Feuerstadt P
Drugs; 2022 Oct; 82(15):1527-1538. PubMed ID: 36287379
[TBL] [Abstract][Full Text] [Related]
6. SER-109 (VOWST
Blair HA
Drugs; 2024 Mar; 84(3):329-336. PubMed ID: 38441806
[TBL] [Abstract][Full Text] [Related]
7. Therapeutics for
Khanna S; Voth E
Expert Rev Gastroenterol Hepatol; 2023; 17(9):903-911. PubMed ID: 37606962
[TBL] [Abstract][Full Text] [Related]
8. Changes in microbial ecology after fecal microbiota transplantation for recurrent C. difficile infection affected by underlying inflammatory bowel disease.
Khanna S; Vazquez-Baeza Y; González A; Weiss S; Schmidt B; Muñiz-Pedrogo DA; Rainey JF; Kammer P; Nelson H; Sadowsky M; Khoruts A; Farrugia SL; Knight R; Pardi DS; Kashyap PC
Microbiome; 2017 May; 5(1):55. PubMed ID: 28506317
[TBL] [Abstract][Full Text] [Related]
9. Clostridioides difficile infections; new treatments and future perspectives.
Normington C; Chilton CH; Buckley AM
Curr Opin Gastroenterol; 2024 Jan; 40(1):7-13. PubMed ID: 37942659
[TBL] [Abstract][Full Text] [Related]
10. Review Article: Safety of Live Biotherapeutic Products Used for the Prevention of Clostridioides difficile Infection Recurrence.
Gonzales-Luna AJ; Carlson TJ; Garey KW
Clin Infect Dis; 2023 Dec; 77(Suppl 6):S487-S496. PubMed ID: 38051970
[TBL] [Abstract][Full Text] [Related]
11. Diluted Fecal Community Transplant Restores Clostridioides difficile Colonization Resistance to Antibiotic-Perturbed Murine Communities.
Lesniak NA; Tomkovich S; Henry A; Taylor A; Colovas J; Bishop L; McBride K; Schloss PD
mBio; 2022 Aug; 13(4):e0136422. PubMed ID: 35913161
[TBL] [Abstract][Full Text] [Related]
12. A Comparison of Currently Available and Investigational Fecal Microbiota Transplant Products for Recurrent
Wang Y; Hunt A; Danziger L; Drwiega EN
Antibiotics (Basel); 2024 May; 13(5):. PubMed ID: 38786164
[No Abstract] [Full Text] [Related]
13. Microbial ecology between
Kamiya S
Biosci Microbiota Food Health; 2023; 42(4):229-235. PubMed ID: 37791342
[No Abstract] [Full Text] [Related]
14. Fecal Microbiota Transplantation Increases Colonic IL-25 and Dampens Tissue Inflammation in Patients with Recurrent Clostridioides difficile.
Jan N; Hays RA; Oakland DN; Kumar P; Ramakrishnan G; Behm BW; Petri WA; Marie C
mSphere; 2021 Oct; 6(5):e0066921. PubMed ID: 34704776
[TBL] [Abstract][Full Text] [Related]
15. Alteration of gut microbial composition associated with the therapeutic efficacy of fecal microbiota transplantation in Clostridium difficile infection.
Lee PC; Chang TE; Wang YP; Lee KC; Lin YT; Chiou JJ; Huang CW; Yang UC; Li FY; Huang HC; Wu CY; Huang YH; Hou MC
J Formos Med Assoc; 2022 Sep; 121(9):1636-1646. PubMed ID: 34836663
[TBL] [Abstract][Full Text] [Related]
16. A profile of the live biotherapeutic product RBX2660 and its role in preventing recurrent
Chopra T
Expert Rev Anti Infect Ther; 2023 Mar; 21(3):243-253. PubMed ID: 36756869
[TBL] [Abstract][Full Text] [Related]
17. Current and future trends in clostridioides (clostridium) difficile infection management.
Khanna S; Gerding DN
Anaerobe; 2019 Aug; 58():95-102. PubMed ID: 31054313
[TBL] [Abstract][Full Text] [Related]
18. Gut microbiota differs between treatment outcomes early after fecal microbiota transplantation against recurrent
Wei S; Bahl MI; Baunwall SMD; Dahlerup JF; Hvas CL; Licht TR
Gut Microbes; 2022; 14(1):2084306. PubMed ID: 36519447
[TBL] [Abstract][Full Text] [Related]
19. Fecal microbiota transplantation: a review on current formulations in
Rakotonirina A; Galperine T; Allémann E
Expert Opin Biol Ther; 2022 Jul; 22(7):929-944. PubMed ID: 35763604
[TBL] [Abstract][Full Text] [Related]
20. Advancing therapeutics for recurrent clostridioides difficile infections: an overview of vowst's FDA approval and implications.
Jain N; Umar TP; Fahner AF; Gibietis V
Gut Microbes; 2023; 15(1):2232137. PubMed ID: 37431860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
